Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
SPONSORED CONTENTAre Your Patients Fully Protected?Fleas, ticks, heartworms, and intestinal parasites—dogs face multiple threats. See how a multi-parasite approach can offer your patients a broad range of protection. + Learn More